The presence of regional metastases of laryngeal cancer differs depending on the location of the tumor and has an influence on the overall survival. The aim of this work is to analyze the frequency and characteristics of regional metastases T1 and T2 of laryngeal carcinoma in relation to the primary tumor location, and their effect on the overall survival. A retrospective study, conducted in the period between 2002 and 2012, that analyzed 445 patients who were surgically treated for laryngeal cancer of T1 and T2 category. The first group consisted of 397 patients without regional metastases, while the second group consisted of 48 patients with regional metastases. A three-year survival is followed, as well as the testing of potential predictors of outcomes by methods of regression. Regional metastases were present in 3.1% of patients with glottic carcinoma of T1 and T2 category, while 43.5% of patients with T1 and T2 supraglottis carcinoma had regional metastases. In the group with regional metastases, there is no statistically significant difference in the occurrence of extracapsular extension in relation to the tumor location, p = 0.7027. The three-year survival rate of patients without regional metastasis is 93.95%, while the survival of patients with regional metastases is 68,75%, p = 0.000. The tumor location (95% CI -1.4716 to -0.0497, P = 0.0369), and the presence of regional metastases (95% CI -1.6300 to -0.0253, P = 0.0443), were identified as predictors of outcomes by multifactorial analysis. Regional metastases in T1 and T2 laryngeal cancer are more common in patients with supraglottic carcinoma. The presence of regional metastases significantly reduces the three-year overall survival.
Hörmann K, Sadick H. Role of surgery in the management of head and neck cancer: a conteporary view of the data in the era of organ preservation. J Laryngol Otol. 2013;(2):121–7.
2.
Ferlito A, Haigentz M, Bradley P, Suarez C, Strojan P. Causes of death of patients with laryngeal cancer. Eur Arch Otorhinolaryngol. 2014;425–34.
3.
Siegel R, Miller K, Jemal A. Cancer Statistics. 2016;7–30.
4.
Hoffman H, Porter K, Karnell L, Cooper J, Weber R. The Laryngoscope. 2006;1–13.
5.
Pezier T, Nixon I, Joshi A, Guerrero-Urbano T, Oakley R. Factors predictive of outcome following primary total laryngectomy for advanced squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2014;(9):2503–9.
6.
Piazza C, Ribeiro J. Anatomy and physiology of the Larynx and Hypopharynx. :461–71.
7.
Mumovi G. Terapija disfonije posle parcijalnih laringektomija primenom kompresije larinksa. doktorska disertacija. 2008;
8.
Markou K, Christoforidou A, Karasmanis I, Tsiropoulos G, Triaridis S, Constantinidis I. Laryngeal cancer: epidemiological data from Northern Greece and review of the literature. Hippokratioa. 2013;(4):313–8.
9.
Chatenoud L, Garvello W, Pagan E, Bertuccio P, Gallus S, Vecchia C. Laryngeal cancer mortality trends ine European countries. Int J Cancer. 2016;(4):833–42.
10.
Jovi R, Miladinov M, Mitrovi K, S. Some epidemiological characteristics of laryngeal cancer in the province of Vojvodina from 1985 to 1996. Arch Oncology. 2001;(1):17–9.
11.
Gallus S, Bosetti C, Franceschi S, Levi F, Negri E. Laryngeal Cancer in Women. Tobacco, Alcohol, Nutritinal and Hormonal Factors. biomarkers & prevention. 2003;(6):514–7.
12.
Spector G, Sessions D, Lenox J, Newland D, Simpson J, Haughey B. Management of stage IV glottis carcinoma: therapeutic outcomes. Laryngoscope. 2004;(8):1438–46.
13.
Van Dijk B, He KK, Coeberg J, Marres H, De Vries E. Progress against laryngeal cancer in The Netherlands between. Epidemiology. 1989;(3):674–81.
14.
Mckanzie R, Fgransen E, Balogh J. Comparing treatment outcomes of radiotherapy and surgery in localy advanced carcinoma of the larynx: a comparison limited to patient eligible for surgery. Int J radiat Oncol Biol Phys. 2000;65–71.
15.
Ambrosch P, Fasel A. Functional organ preservation in laryngeal and hypopharyngeal cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012;1–31.
16.
Chera B, Amdur R, Morris C, Kirwan J, Mendenhall W. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2010;(2):461–6.
17.
18.
Jugoslav Gaši 1, Rajko Jovi 2, Slaviša Anti 1. Bojan Boži.
19.
Faculty of Medicine, Clinic of Otorhinolaryngology.
20.
Clinic of Ear, Nose and Throat Diseases.
21.
SUMMARY The presence of regional metastases of laryngeal cancer differs depending on the location of the tumor and has an influence on the overall survival. The aim of this work is to analyze the frequency and characteristics of regional metastases T1 and T2 of laryngeal carcinoma in relation to the primary tumor location, and their effect on the overall survival. A retrospective study, conducted in the period between 2002 and 2012, that analyzed 445 patients who were surgically treated for laryngeal cancer of T1 and T2 category. The first group consisted of 397 patients without regional metastases, while the second group consisted of 48 patients with regional metastases. A three-year survival is followed, as well as the testing of potential predictors of outcomes by methods of regression. Regional metastases were present in 3.1% of patients with glottic carcinoma of T1 and T2 category, while 43.5% of patients with T1 and T2 supraglottis carcinoma had regional metastases. In the group with regional metastases, there is no statistically significant difference in the occurrence of extracapsular extension in relation to the tumor location, p = 0.7027. The three-year survival rate of patients without regional metastasis is 93.95%, while the survival of patients with regional metastases is 68.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
